The AAV contract development and manufacturing organizations market size was estimated at US$ 555.04 million in 2022 it is predicted to grow at a CAGR of 17.16% from 2023 to 2032 to reach around US$ 2,704.69 million by the end of 2032.
The AAV contract development and manufacturing organizations market report offers an exclusive study of the present state expected at the market dynamics, opportunities, market scheme, growth analysis and regional outlook. The report presents energetic visions to conclude and study the market size, market aspiration, and competitive environment. The research also focuses on the important achievements of the market, research & development, and regional (country by country) growth of the leading vendors operating in the market
The study offers intricate dynamics about different aspects of the global AAV contract development and manufacturing organizations market, which aids companies operating in the market in making strategies development decisions. The study also elaborates on remarkable changes that are highly anticipated to configure growth of the global AAV contract development and manufacturing organizations market during the forecast period. It also includes a key indicator analysis that highlights growth prospects of this market and approximate statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).
Sample Link @ https://www.visionresearchreports.com/report/sample/40034
Report Scope of the AAV Contract Development And Manufacturing Organizations Market
| Report Coverage | Details |
| Market Size in 2022 | USD 555.04 million |
| Revenue Forecast by 2032 | USD 2,704.69 million |
| Growth rate from 2023 to 2032 | CAGR of 17.16% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Covered | Thermo Fischer Scientific, Inc.; Creative Biogene, Catalent Inc.; Charles River Laboratories International, Inc.; Danaher (Aldevron); Forge Biologics, Genezen; ViroCell Biologics; Merck KGaA; VIRALGEN; Biovian Oy; Esco Lifesciences (Esco Aster Pte. Ltd.); GenScript ProBio; Porton Advanced Solution Ltd.; Ask Bio; Showa Denko; Takara Bio, Inc.; ABL Manufacturing, Oxford Biomedica; Belief Biomed, Inc.; Beijing Anlong Biomedicine Co. Ltd.; Forecyte Bio Limited; Gene Pharma, Inc.; Skyline Therapeutics; TFBS Bioscience, Inc. |
This study covers an elaborate segmentation of the global AAV contract development and manufacturing organizations market, along with important information and a competition outlook. The report mentions company profiles of players that are currently influence the global AAV contract development and manufacturing organizations market, wherein various developments, expansions, and winning strategies practiced and execute by leading players have been presented in detail.
AAV Contract Development And Manufacturing Organizations Market Segmentations:
By Workflow
- Upstream Processing
- Vector Amplification & Expansion
- Vector Recovery & Harvesting
- Downstream Processing
- Purification
- Fill Finish
By Culture Type
- Adherent Culture
- Suspension Culture
By Application
- Cell & Gene Therapy Development
- Vaccine Development
- Biopharmaceutical & Pharmaceutical Discovery
- Biomedical Research
By End-user
- Pharmaceutical & Biopharmaceutical Companies
- Academic & Research Institutes
Research Methodology
The research methodology acquire by analysts for assemble the global AAV contract development and manufacturing organizations market report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts study numerous annual report declaration, white papers, market association declaration, and company websites to obtain the necessary understanding of the global AAV contract development and manufacturing organizations market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on AAV Contract Development And Manufacturing Organizations Market
5.1. COVID-19 Landscape: AAV Contract Development And Manufacturing Organizations Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global AAV Contract Development And Manufacturing Organizations Market, By Workflow
8.1. AAV Contract Development And Manufacturing Organizations Market, by Workflow, 2023-2032
8.1.1. Upstream Processing
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Downstream Processing
8.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global AAV Contract Development And Manufacturing Organizations Market, By Culture Type
9.1. AAV Contract Development And Manufacturing Organizations Market, by Culture Type, 2023-2032
9.1.1. Adherent Culture
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Suspension Culture
9.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global AAV Contract Development And Manufacturing Organizations Market, By Application
10.1. AAV Contract Development And Manufacturing Organizations Market, by Application, 2023-2032
10.1.1. Cell & Gene Therapy Development
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Vaccine Development
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Biopharmaceutical & Pharmaceutical Discovery
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Biomedical Research
10.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global AAV Contract Development And Manufacturing Organizations Market, By End-user
11.1. AAV Contract Development And Manufacturing Organizations Market, by End-user, 2023-2032
11.1.1. Pharmaceutical & Biopharmaceutical Companies
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Academic & Research Institutes
11.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global AAV Contract Development And Manufacturing Organizations Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Workflow (2020-2032)
12.1.2. Market Revenue and Forecast, by Culture Type (2020-2032)
12.1.3. Market Revenue and Forecast, by Application (2020-2032)
12.1.4. Market Revenue and Forecast, by End-user (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Workflow (2020-2032)
12.1.5.2. Market Revenue and Forecast, by Culture Type (2020-2032)
12.1.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.1.5.4. Market Revenue and Forecast, by End-user (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Workflow (2020-2032)
12.1.6.2. Market Revenue and Forecast, by Culture Type (2020-2032)
12.1.6.3. Market Revenue and Forecast, by Application (2020-2032)
12.1.6.4. Market Revenue and Forecast, by End-user (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Workflow (2020-2032)
12.2.2. Market Revenue and Forecast, by Culture Type (2020-2032)
12.2.3. Market Revenue and Forecast, by Application (2020-2032)
12.2.4. Market Revenue and Forecast, by End-user (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Workflow (2020-2032)
12.2.5.2. Market Revenue and Forecast, by Culture Type (2020-2032)
12.2.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.2.5.4. Market Revenue and Forecast, by End-user (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Workflow (2020-2032)
12.2.6.2. Market Revenue and Forecast, by Culture Type (2020-2032)
12.2.6.3. Market Revenue and Forecast, by Application (2020-2032)
12.2.6.4. Market Revenue and Forecast, by End-user (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Workflow (2020-2032)
12.2.7.2. Market Revenue and Forecast, by Culture Type (2020-2032)
12.2.7.3. Market Revenue and Forecast, by Application (2020-2032)
12.2.7.4. Market Revenue and Forecast, by End-user (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Workflow (2020-2032)
12.2.8.2. Market Revenue and Forecast, by Culture Type (2020-2032)
12.2.8.3. Market Revenue and Forecast, by Application (2020-2032)
12.2.8.4. Market Revenue and Forecast, by End-user (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Workflow (2020-2032)
12.3.2. Market Revenue and Forecast, by Culture Type (2020-2032)
12.3.3. Market Revenue and Forecast, by Application (2020-2032)
12.3.4. Market Revenue and Forecast, by End-user (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Workflow (2020-2032)
12.3.5.2. Market Revenue and Forecast, by Culture Type (2020-2032)
12.3.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.3.5.4. Market Revenue and Forecast, by End-user (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Workflow (2020-2032)
12.3.6.2. Market Revenue and Forecast, by Culture Type (2020-2032)
12.3.6.3. Market Revenue and Forecast, by Application (2020-2032)
12.3.6.4. Market Revenue and Forecast, by End-user (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Workflow (2020-2032)
12.3.7.2. Market Revenue and Forecast, by Culture Type (2020-2032)
12.3.7.3. Market Revenue and Forecast, by Application (2020-2032)
12.3.7.4. Market Revenue and Forecast, by End-user (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Workflow (2020-2032)
12.3.8.2. Market Revenue and Forecast, by Culture Type (2020-2032)
12.3.8.3. Market Revenue and Forecast, by Application (2020-2032)
12.3.8.4. Market Revenue and Forecast, by End-user (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Workflow (2020-2032)
12.4.2. Market Revenue and Forecast, by Culture Type (2020-2032)
12.4.3. Market Revenue and Forecast, by Application (2020-2032)
12.4.4. Market Revenue and Forecast, by End-user (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Workflow (2020-2032)
12.4.5.2. Market Revenue and Forecast, by Culture Type (2020-2032)
12.4.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.4.5.4. Market Revenue and Forecast, by End-user (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Workflow (2020-2032)
12.4.6.2. Market Revenue and Forecast, by Culture Type (2020-2032)
12.4.6.3. Market Revenue and Forecast, by Application (2020-2032)
12.4.6.4. Market Revenue and Forecast, by End-user (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Workflow (2020-2032)
12.4.7.2. Market Revenue and Forecast, by Culture Type (2020-2032)
12.4.7.3. Market Revenue and Forecast, by Application (2020-2032)
12.4.7.4. Market Revenue and Forecast, by End-user (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Workflow (2020-2032)
12.4.8.2. Market Revenue and Forecast, by Culture Type (2020-2032)
12.4.8.3. Market Revenue and Forecast, by Application (2020-2032)
12.4.8.4. Market Revenue and Forecast, by End-user (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Workflow (2020-2032)
12.5.2. Market Revenue and Forecast, by Culture Type (2020-2032)
12.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.5.4. Market Revenue and Forecast, by End-user (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Workflow (2020-2032)
12.5.5.2. Market Revenue and Forecast, by Culture Type (2020-2032)
12.5.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.5.5.4. Market Revenue and Forecast, by End-user (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Workflow (2020-2032)
12.5.6.2. Market Revenue and Forecast, by Culture Type (2020-2032)
12.5.6.3. Market Revenue and Forecast, by Application (2020-2032)
12.5.6.4. Market Revenue and Forecast, by End-user (2020-2032)
Chapter 13. Company Profiles
13.1. Thermo Fischer Scientific, Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Creative Biogene
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Catalent Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Charles River Laboratories International, Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Danaher (Aldevron)
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Forge Biologics
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Genezen
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. ViroCell Biologics
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Merck KGaA
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. VIRALGEN
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Contact Us:
Vision Research Reports
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168